ZWEI Wealth Experts
Acquisition in 2025
Founded in Zurich, Switzerland in 2014, ZWEI Wealth Experts is a wealth management firm dedicated to providing independent advisory services. It focuses on delivering transparency and control to investors by acting as an independent advisor.
DataBank
Secondary Market in 2022
DataBank Holdings, Ltd. is a data center and co-location company headquartered in Dallas, Texas, with additional facilities in the Dallas/Fort Worth area, Minneapolis/St. Paul, Eagan, Kansas City, and Atlanta. Founded in 2004, DataBank provides a comprehensive array of services, including co-location solutions that ensure security, power configurations, and cooling. The company also offers managed services such as cloud computing, virtual hosting, network connectivity, and security, along with consulting services that encompass design and implementation, migration, and continuity planning. DataBank emphasizes compliance with various industry standards, including those for payment card security and health data protection. Catering to a diverse clientele across sectors like healthcare, finance, gaming, and hospitality, DataBank is committed to optimizing IT environments and ensuring data availability for enterprises.
Upmin is a real estate technology company that operates an online platform for property management. It automates various processes such as accounting, utility bill payments, tenant management, and property maintenance, saving landlords and owners time and money. Additionally, Upmin offers optional rental services including tenant search assistance from advertising to handover.
PriceHubble
Series B in 2021
PriceHubble is a Swiss B2B proptech company that provides innovative digital solutions for the real estate industry. Leveraging big data and advanced analytics, PriceHubble offers accurate property valuations and market insights to enhance decision-making across the entire real estate value chain, including banks, asset managers, developers, and agents. Active in nine countries with over 130 employees worldwide.
Zenhomes provides a one-stop shop for private landlords and property managers. The company's digital platform simplifies property and tenant management.
Vermietet.de
Venture Round in 2019
Vermietet.de is a Berlin-based company that aims to simplify and enhance real estate ownership through its innovative property management platform. Recognizing the complexities involved in property management, the company provides tools that assist property owners in handling various administrative tasks, including document creation, property maintenance, tenant search, and communication. By streamlining these processes, Vermietet.de enables landlords to efficiently manage property valuation, utility cost calculations, and monthly rental payment checks, making property management more transparent and user-friendly.
Fincentrum
Acquisition in 2018
Fincentrum is one of the leading financial advisory consulting firms in the Czech Republic, renowned for its commitment to high-quality advisory services that prioritize client interests. The company assists individuals and businesses in navigating the complexities of finance by providing access to a wide range of financial institutions and their products. These offerings include insurance, loans, investments, savings, and pension solutions, which cater to diverse financial needs. By leveraging partnerships with various financial entities, Fincentrum ensures that its clients receive tailored advice and solutions to effectively address their unique financial situations.
LaFinBox
Venture Round in 2018
LaFinBox is a free and secure mobile application designed to manage money across various financial institutions. Established in 2015 by Swiss Life, a prominent player in the insurance and wealth management sector since 1857, LaFinBox centralizes all financial and investment support, including current accounts, bank cards, loans, passbooks, employee savings, life insurance, PEA, mortgage, and more. The app aims to provide users with a comprehensive overview of their finances, making it easier to manage and track their financial activities.
PriceHubble
Series A in 2017
PriceHubble is a Swiss B2B proptech company that provides innovative digital solutions for the real estate industry. Leveraging big data and advanced analytics, PriceHubble offers accurate property valuations and market insights to enhance decision-making across the entire real estate value chain, including banks, asset managers, developers, and agents. Active in nine countries with over 130 employees worldwide.
Bexio
Venture Round in 2017
Bexio AG is a Swiss company that specializes in providing cloud-based business and accounting software tailored for small and medium-sized enterprises. Founded in 2013 and based in Rapperswil, the company was previously known as easySYS AG before rebranding in 2015. Bexio AG focuses on simplifying accounting processes and enhancing business management through its user-friendly platform, which employs a standardized interface to facilitate interactions between businesses and their trustees, banks, and service providers. As of mid-2018, Bexio operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG, reflecting its commitment to supporting the growth and efficiency of small businesses in Switzerland.
Phenex Pharmaceuticals
Series C in 2010
Phenex Pharmaceuticals AG is a privately held drug discovery and development company based in Ludwigshafen, Germany, with additional facilities in Heidelberg. Founded in 2002, the company specializes in small-molecule drug discovery, focusing on liver diseases, intestinal diseases, and cancer. Its research includes developing retinoid-acid receptor-related orphan receptor gamma t (RORγt) inverse agonists for autoimmune diseases and farnesoid X receptor (FXR) agonists for non-alcoholic steatohepatitis. Phenex aims to identify novel molecular mechanisms and develop innovative therapeutics, having already translated two such mechanisms into proprietary small molecules.
AWD Holding
Acquisition in 2007
AWD Holding AG, along with its subsidiaries, provides individual financial advice and planning services in Europe. It focuses on provision of hedge fund and old-age pension products, and long-term growth of assets. The company provides retirement provision services; and private asset accumulation and asset retirement planning services for private customers. It serves customers in Germany, Austria, Czech Republic, Hungary, Poland, Slovakia, Great Britain, and Switzerland. AWD Holding AG was formerly known as Allgemeiner Wirtschaftsdienst. The company was founded in 1988 and is based in Hanover, Germany. It has independent representative offices in Germany, the United Kingdom, Austria, Switzerland, and Central and Eastern Europe. AWD Holding AG operates as a subsidiary of Swiss Life Deutschland Holding GmbH.
Enanta Pharmaceuticals
Venture Round in 2004
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for viral infections and liver diseases. Its research targets include respiratory syncytial virus, hepatitis B virus, hepatitis C virus and nonalcoholic steatohepatitis, as well as other viral pathogens such as SARS-CoV-2 and human metapneumovirus. The company develops HCV therapies, including protease inhibitors such as glecaprevir, and collaborates with AbbVie to identify, develop, and commercialize NS3 and NS3/4A protease inhibitor compounds. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.
Iolon, Inc. is a privately held company specializing in optical networking components, focusing on high-performance tunable devices for advanced fiber optic networks. The company's initial product is a high-powered external cavity tunable laser source, designed for high bit rate and long-haul applications. Iolon also plans to expand its product offerings to include tunable filters, optical switches, polarization controllers, spectral monitors, and universal transponders. The company leverages its platform technology, which incorporates patented micro-optics, MEMS, and advanced servo control technologies, to facilitate advanced automation for high-volume manufacturing. Iolon's products are critical for transmitting, monitoring, and receiving optical signals within optical networks and for test and measurement equipment.
Zeptosens
Series B in 2001
Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development.
In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions.
Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.
Acorda Therapeutics
Series A in 2001
Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.